References
- Scaldaferri F, Fiocchi C. Inflammatory bowel disease: progress and current concepts of etiopathogenesis. J. Dig. Dis.4, 171–178 (2007).
- Duerr RH, Taylor KD, Brant SR et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science314, 1461–1463 (2006).
- Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature448, 427–434 (2007).
- Pizarro TT, Cominelli F. Cytochine therapy for Crohn’s disease: advances in translational research. Annu. Rev. Med.58, 433–444 (2007).
- Annunziato F, Cosmi L, Santarlasci V et al. Phenotipic and functional features of human Th 17 cells. J. Exp. Med.204, 1849–1861 (2007).
- Fujino S, Andoh A, Bamba S et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut52(1), 65–70 (2003).
- Maloy KJ. The interleukin-23/interleukin-17 axis in intestinal inflammation. J. Intern. Med.263, 584–590 (2008).
- Papadakis KA, Targan SR. Role of cytochines in the pathogenesis of inflammatory bowel disease. Ann. Rev. Med.51, 289–298 (2000).
- Fuss IJ, Neurath M, Boirivant M et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease: Crohn’s disease LP cells manifest increased secretion of IFN-γ, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J. Immunol.157, 1261–1270 (1996).
- Murch SH, Lamkin VA, Savage MO et al. Serum concentrations of tumour necrosis factor α in childhood chronic inflammatory bowel disease. Gut32, 913–917 (1991).
- Murch SH, Braegger CP, Walker-Smith JA et al. Location of tumour necrosis factor α by immunohistochemistry in chronic inflammatory bowel disease. Gut34, 1705–1709 (1993).
- Braegger CP, Nicholls S, Murch SH et al. Tumour necrosis factor α in stool as a marker of intestinal inflammation. Lancet339, 89–91 (1992).
- Danese S. Nonimmune cells in inflammatory bowel disease: from victim to villain. Trends Immunol.29, 555–564 (2008).
- Shanahan F. Anti-TNF therapy for Crohn’s disease: a perspective (infliximab is not the drug we have been waiting for). Inflamm. Bowel Dis.6, 137–139 (2000).
- Plevy SE, Landres CJ, Prehn J et al. A role for TNFα and mucosal T helper-1 cytokines in the pathogenesis of Crohn’s disease. J. Immunol.59, 62–76 (1997).
- Papadakis KA, Targan SR. Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology119, 1148–1157 (2000).
- Targan SR, Hanauer SB, Van Deventer SJ et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn’s disease. Crohn’s Disease cA2 Study Group. N. Engl. J. Med.337, 1029–1035 (1997).
- Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomized trial. Lancet359, 1541–1549 (2002).
- Present DH, Rutgeerts P, Targan SR et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N. Engl. J. Med.340, 1398–1405 (1999).
- Sands BE, Blank MA, Patel K et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N. Engl. J. Med.350, 934–936 (2004).
- Lichtenstein GR, Bala M, Han C et al. Infliximab improves quality of life in patients with Crohn’s disease. Inflamm. Bowel Dis.8, 237–243 (2002).
- Lichtenstein GR, Feagan BG, Cohen RD et al. Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry. Clin. Gastroenterol. Hepatol.4, 621–630 (2006).
- Van Den Bosch F, Kruithof E, Baeten D et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum.46, 755–765 (2002).
- Braun J, Brandt J, Listing J et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet358, 1187–1193 (2002).
- Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor α. N. Engl. J. Med.346, 1349–1356 (2002).
- Brooklyn T, Shetty A, Bowden J et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double-blind placebo controlled trial. Gastroenterology128(4 Suppl. 2), A-26 (2005) (Abstract A-146).
- Joseph A, Raj D, Dua HS et al. Infliximab in the treatment of refractory posterior uveitis. Ophthalmology110, 1449–1453 (2003).
- El-Shabrawi Y, Hermann J. Anti-tumor necrosis factor-α therapy with infliximab as an alternative to corticosteroids in the treatment of human leucocyte antigen B27-associated acute anterior uveitis. Ophthalmology109, 2342–2346 (2002).
- Hyams J, Crandal W, Kugathasan S et al. Induction and maintenance infliximab therapy for the treatment of moderate to severe Crohn’s disease in children. Gastroenterology132, 863–873 (2007).
- Rutgeerts P, Feagan BG, Olson A et al. A randomized placebo-controlled trial of infliximab therapy for active ulcerative colitis: act I trial. Gastroenterology 128(4 Suppl. 2), A-105 (2005) (Abstract 889).
- Sandborn WJ, Rachmilewitz D, Hanauer SB et al. Infliximab induction and maintenance therapy for ulcerative colitis: the Act 2 trial. Gastroenterology 128(4 Suppl. 2), A-104 (2005) (Abstract 688).
- Nesbitt A, Fossati G, Bergin M et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor a agents. Inflamm. Bowel Dis.13, 1323–1332 (2007).
- Hanauer SB, Sandborn WJ, Rutgeerts P et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology130, 323–333 (2006).
- Sandborn WJ, Hanauer SB, Rutgeerts P et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut56, 1232–1239 (2007).
- Colombel JF, Sandborn WJ, Rutgeerts P et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology132, 52–65 (2007).
- Colombel JF, Schwartz MK et al. Sustainability of adalimumab in fistula healing and response: 2-year data from CHARM and 12 month open-label extension follow-up study. Am. J. Gastroenterol.102, S497 (2007).
- Sandborn WJ, Rutgeerts P, Enns R et al. Adalimumab induction therapy for Crohn’s disease previously treated with infliximab. Ann. Intern. Med.146, 829–838 (2007).
- Sandborn WJ, Feagan BG, Stoinov S et al. Certolizumab pegol for the treatment of Crohn’s disease. N. Engl. J. Med.357, 228–238 (2007).
- Schreiber S, Rutgeerts P, Fedorak RNN et al. A randomised, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn’s disease. Gastroenterology129, 807–818 (2005).
- Schreiber S, Khaliq-Kareemi M, Lawrance IC et al. Maintenance therapy with certolizumab pegol for Crohn’s disease. N. Engl. J. Med.357, 239–250 (2007).
- Vermeire S, Abreu MT, D’Haens G et al. Assessment of certolizumab pegol in the treatment of Crohn’s disease patients for whom infliximab treatment was not successful: open-label induction preliminary results from the WELCOME study. J. Crohn’s Colitis2, 4 (2008) (Abstract 9).
- Caprilli R, Angelucci E, Cocco A et al. Early or late guided missile in the treatment of Crohn’s disease? Dig. Liv. Dis.37, 973–979 (2005).
- Hanauer SB. Clinical perspectives in Crohn’s disease. Turning traditional treatment strategies on their heads: current evidence for “step-up” versus “top-down”. Rev. Gastroenterol. Disord.7(Suppl. 2), S17–S22 (2007).
- Baert P, Caprilli R, Angelucci E et al. Medical therapy for Crohn’s disease: top-down or step-up? Dig. Dis.25, 260–266 (2007).
- Oldenburg B, Hommes D. Biological therapies in inflammatory bowel disease: top-down or bottom-up? Curr. Opin. Gastroenterol.23, 395–399 (2007).
- Hommes D, Baert F, Van Assche G et al. A randomized controlled trial evaluating the ideal medical management for Crohn’s disease (CD): top-down versus step-up strategies. Gastroenterology128(Suppl. 2), A577 (2005).
- D’Haens G, Baert F, Van Assche G et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet371, 660–667 (2008).
- Saro C, Da La Coba C, Casado MA et al. Resource use in patients with Crohn’s disease treated with infliximab. Aliment. Pharmacol. Ther.26, 1313–1323 (2007).
- Kaplan GG, Hur C, Korzenik J et al. Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn’s disease: a cost–effectiveness analysis. Aliment. Pharmacol. Ther.26, 1509–1520 (2007).
- Viget N, Vernier-Massouille G, Salmon-Ceron D et al. Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. Gut57, 549–558 (2008).
- Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N. Engl. J. Med.345, 1098–1104 (2001).
- Hommes DW, Oldenburg B, Van Bodegraven AA et al. Guidelines for treatment with infliximab for Crohn’s disease. Neth. J. Med.64, 219–229 (2006).
- Wolfe F, Michaud K, Anderson J et al. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arth. Rheum.50, 372–379 (2004).
- Wallis RS, Broder MS, Wong JY et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin. Infect. Dis.38, 1261–1265 (2004).
- Gomez-Reino JJ, Carmona L, Valverde VR et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arth. Rheum.48, 2122–2127 (2003).
- Colombel JF, Loftus EV, Tremaine WJ et al. The safety profile of infliximab in patients with Crohn’s disease: the Mayo Clinic experience in 500 patients. Gastroenterology126, 19–31 (2004).
- Theis VS, Rhodes JM. Review article: minimizing tuberculosis during anti-tumor necrosis factor-α treatment in inflammatory bowel disease. Aliment. Pharmacol. Ther.27, 19–30 (2008).
- British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF α treatment. Thorax60, 800–805 (2005).
- Rampton DS. Preventing TB in patients with Crohn’s disease needing infliximab or other anti-TNF therapy. Gut54, 1360–1362 (2005).
- Kunst H. Diagnosis of latent tuberculosis infection: the potential role of new technologies. Respir. Med.100, 2098–2106 (2006).
- Mow WS, Abreu-Martin MT, Papadakis KA et al. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin. Gastroenterol. Hepatol.2, 309–313 (2004).
- Efthimiou P, Sood S. QuantiFERON TB Gold test: the new standard for screening of latent tuberculosis in patients with rheumatoid arthritis. Ann. Rheum. Dis.66, 276 (2007).
- Ravn P, Munk ME, Andersen AB et al. Reactivation of tuberculosis during immunosuppressive treatment in a patient with a positive QuantiFERON-RD1 test. Scand. J. Infect. Dis.36, 499–501 (2004).
- Matulis G, Jüni P, Villiger PM et al. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases. Performance of Mycobacterium tuberculosis antigen-specific interferon g assays. Ann. Rheum. Dis.67, 84–90 (2008).
- American Thoracic Society. Targeted tuberculin testing and treatment of latent TB infection. Am. J. Resp. Crit. Care161, 221–247 (2000).
- Keane J. TNF-blocking agents and TB. New drugs illuminate and old topic. Rheumatology44, 714–720 (2005).
- Oniankitan O, Duvoux C, Challine D et al. Infliximab therapy for rheumatic disease in patients with chronic hepatitis B or C. J. Rheumatol.31, 107–109 (2004).
- Anelli MG, Torres DD, Manno C et al. Improvement of renal function and disappearance of hepatitis B virus DNA in a patient with rheumatoid arthritis and renal amyloidosis following treatment with infliximab. Arth. Rheum.52, 2519–2520 (2005).
- Ostuni P, Botsios C, Punzi L et al. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose of methotrexate. Ann. Rheum. Dis.62, 686–687 (2003).
- Wendling D, Auge B, Bettinger D et al. Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy. Ann. Rheum. Dis.64, 788–789 (2005).
- Michel M, Duvoux C, Hezode C et al. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for adult onset Still’s disease. J. Rheumatol.30, 1624–1625 (2003).
- Ueno Y, Tanaka S, Shimamoto M et al. Infliximab therapy for Crohn’s disease in a patient with chronic hepatitis B. Dig. Dis. Sci.50, 163–166 (2005).
- Esteve M, Saro C, Gonzalez-Huix F et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxis. Gut53, 1363–1365 (2004).
- Calabrese LH, Zein N, Vassilopoulos D. Safety of antitumor necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann. Rheum. Dis.63, 18–24 (2004).
- Del Valle Garcia-Sanchez M, Gomez-Camacho F, Poyato-Gonzalez A et al. Infliximab therapy in a patient with Crohn’s disease and chronic hepatitis virus infection. Inflamm. Bowel Dis.10, 701–702 (2004).
- Roux CH, Brocq O, Breuil V et al. Safety of anti-TNF-α therapy in rheumatoid arthritis and spondyloarthropathies with concurrent B or C chronic hepatitis. Rheumatology45, 1294–1297 (2006).
- Carroll MB, Bond IB. Use of tumor necrosis factor-α inhibitors in patients with chronic hepatitis B infection. Semin. Arthritis Rheum.38(3), 208–217 (2008).
- Siegel CA, Marden SM, Persing SM, et al. Risk of lymphoma associated with anti-TNF agents for the treatment of Crohn’s disease: a meta-analysis. Gastroenterology134(Suppl. 1), A-144 (2008) (Abstract A 970).
- Shale M, Kanfer E, Panaccione R et al. Hepatosplenic T cell lymphoma in inflammatory bowel disease. Gut57, 1639–1641 (2008).
- Thomas CW Jr, Weinshenker BG, Sandboure WJ et al. Demyelination during anti-tumor necrosis factor α therapy with infliximab for Crohn’s disease. Inflamm. Bowel Dis.10, 28–31 (2004).
- Chung ES, Packer M, Lo KH et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive heart failure (ATTACH) trial. Circulation107, 3133–3140 (2003).
- Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ. Res.91, 988–998 (2002).
- Baert F, Norman M, Vermeire S et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N. Engl. J. Med.348, 601–608 (2003).
- Rutgeerts P, Feagan BG, Lichtenstein GR et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology126, 402–413 (2004).
- Sands BE, Anderson FH, Bernstein CN et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N. Engl. J. Med.350, 876–885 (2004).
- Maser EA, Villela R, Silverberg MS et al. Association of through serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn’s disease. Clin. Gastroenterol. Hepatol.4, 1248–1254 (2006).
- Farrell RJ, Alsahli M, Jeen YT S et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn’s disease: a randomized clinical trial. Gastroenterology124, 917–924 (2003).
- Fidder H, Schnitzler F, Ferrante M et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut58, 501–508 (2009).
- Korzenik JR, Podolsky DK. Evolving knowledge and therapy of inflammatory bowel disease. Nat. Rev. Drug Discov.5, 197–209 (2006).
- Peyrin-Biroulet L, Desremaux P, Sandborn WJ, Colombel JF. Crohn’s disease: beyond antagonists of tumour necrosis factor. Lancet372, 67–81 (2008)
- Gately MK, Renzeti LM, Magram J et al. The interleukin-12/interleukin-12 receptor system: role in normal and pathologic immune responses. Annu. Rev. Immunol.16, 495–521 (1998).
- Trinchieri G. Proinflammatory and immunoregulatory functions of interleukin-12. Int. Rev. Immunol.16, 365–396 (1998).
- Cho JH, Weaver CT. The genetics of inflammatory bowel disease. Gastroenterology133, 1327–1339 (2007).
- Mannon PJ, Fuss IJ, Mayer L et al. Anti-interleukin-12 antibody for active Crohn’s disease. N. Engl. J. Med.351, 2069–2079 (2004).
- Sandborn WJ, Feagan BJ, Fedorak R et al. A multicenter, randomized, Phase IIa study of human monoclonal antibody to IL-12/23p40 (CNTO 1275) in patients with moderately to severely active Crohn’s disease. Gastroenterology132(Suppl. 2), A-51 (Abstract 272) (2007).
- Hommes D, Targan S, Baumgart DC et al. A Phase I study: visilizumab therapy in Crohn’s disease (CD) patients refractory to infliximab treatment. Gastroenterology130(Suppl. 2), A-111 (Abstract n769) (2006).
- Lowder JN, Baumgart DC, Hommes DW et al. A Phase I study: visilizumab therapy in Crohn’s disease (CD) patients with perianal fistula. Gut55(Suppl.) (2006) (Abstract A127) .
- Plevy S, Salzberg B, Van Assche G et al. A Phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody in severe steroid-refractory ulcerative colitis. Gastroenterology133, 1414–1422 (2007).
- Canva-Delcambre V, Jacquot S et al. Treatment of severe Crohn’s disease with anti-CD4 monoclonal antibody. Aliment. Pharmacol. Ther.10, 721–727 (1996).
- Stronkhorst A, Radema S, Yong SL et al. CD4 antibody treatment in patients with active Crohn’s disease: a Phase I dose finding study. Gut40, 320–327 (1997).
- Van Assche G, Sandborn WJ, Feagan BG et al. Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial. Gut55, 1568–1574 (2006).
- Creed TJ, Norman MR, Probert CS et al. Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. Aliment. Pharmacol. Ther.18, 65–75 (2003).
- Creed TJ, Probert CS, Norman MR et al. Basiliximab for the treatment of steroid-resistant ulcerative colitis: further experience in moderate and severe disease. Aliment. Pharmacol. Ther.23, 1435–1442 (2006).
- Ito H, Takazoe M, Fukuda Y et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn’s disease. Gastroenterology126, 989–996; discussion 947 (2004).
- Hommes DW, Mikhajlowa TL, Stoinov S et al. Fontolizumab, a humanized anti-interferon γ antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn’s disease. Gut55, 1131–1137 (2006).
- Reinisch W, Hommes DW, Van Assche G et al. A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanized anti-interferon γ antibody, in patients with moderate to severe Crohn’s disease. Gut55, 1138–1144 (2006).
- Dumont FJ. Fontolizumab protein design labs. Curr. Opin. Investig. Drugs6, 537–544 (2005).
- Hynes RO. Integrins: versatility, modulation, and signalling in cell adhesion. Cell69, 11–25 (1992).
- Bevilacqua MP. Endothelial-leukocyte adhesion molecules. Ann. Rev. Immunol.11, 767–804 (1993).
- Feagan BG, Greenberg G, Wild G et al. Efficacy and safety of a humanized α4β7 antibody in active Crohn’s disease (CD). Gastroenterology124, A25–A26 (2003).
- Yacyshyn BR, Chey WY, Wedel MK et al. A randomized, double-masked, placebo-controlled study of molecule 1, for the treatment of subjects with active Crohn’s disease. Clin. Gastroenterol. Hepatol.5, 215–220 (2007).
- Bekker P, Schreiber S, Keshav S et al. PROTECT-1, prospective randomized oral therapy evaluation of CCX282-B (TRAFICET-EN) in Crohn’s disease. Gut56(Suppl.), A23 (2007).
- Ghosh S. Therapeutic value of a-4-integrin blockade in inflammatory bowel disease: the role of natalizumab. Expert Opin. Biol. Ther.3, 995–1000 (2003).
- Langer-Gould A, Atlas SW, Green AJ et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N. Engl. J. Med.353, 375–381 (2005).
- Sandborn WJ, Colombel JF, Enns R et al. Natalizumab induction and maintenance therapy for Crohn’s disease. N. Engl. J. Med.353, 1912–1925 (2005).
- Targan SR, Feagan BG, Fedorak RN et al. Natalizumab for the treatment of active Crohn’s disease: results of the ENCORE trial. Gastroenterology132, 1672–1683 (2007).
- MacDonald JK, McDonald JW. Natalizumab for induction of remission in Crohn’s disease. Cochrane Database Syst. Rev. CD006097 (2007).
- Van Assche G, Van Ranst M, Sciot R et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N. Engl. J. Med.353, 362–368 (2005).
- Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon β-1a for multiple sclerosis. N. Engl. J. Med.353, 369–374 (2005).
- Sandborn WJ, Targan S. A safety evaluation for progressive multifocal leukoencephalopathy (PML) in greater than 3500 patients with Crohn’s disease (CD), multiple sclerosis (MS), and rheumatoid arthritis (RA) previously treated with natalizumab in clinical trials. GastroenterologyA492 (2006).
- Yousry TA, Major EO, Ryschkewitsch C et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N. Engl. J. Med.354, 924–933 (2006).
Websites
- American Thoracic Society. Targeted Tuberculin Testing and Treatment of Latent TB Infection. ATS Guidelines (1999) www.thoracic.org/sections/publications/statements/pages/mtpi/latentTB1–27.html
- Oxford Immnotec (2007) www.oxfordimmunotec.com
- PDL BioPharma news release. PDL BioPharma announces significant strategic and portfolio changes to focus on antibody discovery and development (28 August, 2007) http://phx.corporate-ir.net/phoenix.zhtml?c=100463&p=irol-newsArticle&ID=1045731&highlight (Accessed 16 February 2009)
- Biogen Idec and Elan announce volontary suspension of TysabriR (natalizumab): Elan and Biogen: internet press release, 2005 www.elan.com
- Biogen. TOUCHTM Prescribing Program (2006) www.tysabri.com/touch.html (Accessed 14 August 2006)